Apeloa Pharmaceutical Co.,Ltd

000739

CNE000000Q45

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 23/06/2024 BST			5-day change	1st Jan Change
13.79 ^CNY	-2.27%		-5.35%	-10.40%

06-04	Tranche Update on Apeloa Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on March 27, 2024.	CI
04-17	Apeloa Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Tranche Update on Apeloa Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on March 27, 2024.

June 04, 2024 at 08:31 pm

From March 27, 2024 to May 31, 2024, the company has repurchased 5,735,000 shares, representing 0.49% for CNY 80.24 million. With this, the company has completed the repurchase of 5,735,000 shares, representing 0.49% for CNY 80.24 million under the buyback announced on March 27, 2024.

Latest news about Apeloa Pharmaceutical Co.,Ltd

Tranche Update on Apeloa Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on March 27, 2024.	06-04	CI
Apeloa Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	04-17	CI
Apeloa Pharmaceutical Co.,Ltd Approves Cash Dividend for 2023	04-09	CI
Apeloa Pharmaceutical Co.,Ltd announces an Equity Buyback for CNY 300 million worth of its shares.	03-27	CI
Apeloa Pharmaceutical Co.,Ltd authorizes a Buyback Plan.	03-26	CI
Apeloa Pharmaceutical Co.,Ltd. Proposes Final Dividend for 2023	03-08	CI
Apeloa Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	03-07	CI
Apeloa Pharmaceutical to Co-Develop Antibody Drug Conjugates With Zhenge Biotechnology	03-06	MT
Apeloa Pharmaceutical to Scrap Sofadil for Injection Clinical Trial for Stroke	01-29	MT
Apeloa Pharmaceutical's Profit Climbs 13.6% in Q3	19/10/23	MT
Apeloa Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	18/10/23	CI
Apeloa Pharmaceutical to Cooperate With Wuhan Hopson Technology on Customized Production Projects	18/10/23	MT
Apeloa Pharma Unit Passes US FDA On-Site Inspection	22/09/23	MT
Apeloa Pharmaceutical's Unit Passes US FDA's Inspection	13/09/23	MT
Apeloa Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	14/08/23	CI
Apeloa Pharma Forms Strategic Drug Alliance With Zelgen Biopharma	13/06/23	MT
Apeloa Pharmaceutical to Sell 95% Stake in Injection Unit for 38 Million Yuan	19/05/23	MT
Shanxi Heyang Pharmaceutical Ltd entered into an agreement to acquire 95% stake in Shanxi Puheng Pharmaceutical Co., Ltd from Apeloa Pharmaceutical Co.,Ltd for CNY 38 million	18/05/23	CI
Apeloa Pharmaceutical Co.,Ltd Implements Final Profit Distribution Plan of A Shares for 2022, Payable on 22 May 2023	16/05/23	CI
Apeloa Pharmaceutical Co.,Ltd Approves Election of Pan Weiguang as Independent Director	19/04/23	CI
Apeloa Pharmaceutical Co.,Ltd Approves Cash Dividend for the Year 2022	19/04/23	CI
Apeloa Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	17/04/23	CI
Apeloa Pharmaceutical Co.,Ltd Announces Final Cash Dividend for 2022	10/03/23	CI
Apeloa Pharma’s 2022 Profit Rises 3.5% as Revenue Surges 18%; Shares Slide Nearly 6%	10/03/23	MT
Apeloa Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	09/03/23	CI

Chart Apeloa Pharmaceutical Co.,Ltd

Duration

Period

More charts

Company Profile

Apeloa Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of Active Pharmaceutical Ingredient (API) intermediates, contract development and manufacturing organization (CDMO), preparations and others, as well as import and export trade. The Company operates three businesses. The API intermediates business mainly includes cephalosporin series, penicillin series, psychiatric series, cardiovascular and cerebrovascular series and veterinary API intermediates series. The CDMO business mainly includes research and development services, commercial human drug projects, commercial veterinary drug projects and other commercial products. The preparation business mainly includes anti-infective, cardiovascular and cerebrovascular, psychiatric and anti-tumor preparation products. The Company mainly operates its businesses in domestic and overseas markets.

Sector

Pharmaceuticals

Calendar

14/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Apeloa Pharmaceutical Co.,Ltd

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.57 CNY

Average target price

17.75 CNY

Spread / Average Target

+30.80%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
APELOA PHARMACEUTICAL CO.,LTD	-10.40%	2.19B
ELI LILLY AND COMPANY	+55.19%	815B
NOVO NORDISK A/S	+45.94%	654B
JOHNSON & JOHNSON	-6.09%	354B
MERCK & CO., INC.	+21.92%	337B
ABBVIE INC.	+10.18%	302B
ASTRAZENECA PLC	+18.38%	247B
ROCHE HOLDING AG	+2.62%	229B
NOVARTIS AG	+13.35%	219B
AMGEN INC.	+10.86%	171B

Other Pharmaceuticals

Apeloa Pharmaceutical Co.,Ltd

Equities

000739

CNE000000Q45

Pharmaceuticals

Tranche Update on Apeloa Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on March 27, 2024.

Latest news about Apeloa Pharmaceutical Co.,Ltd

Chart Apeloa Pharmaceutical Co.,Ltd

Company Profile

Income Statement Evolution

Ratings for Apeloa Pharmaceutical Co.,Ltd

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals